Research  >  Research  >  Scientist Profiles  >  Scientists A-F

Scientist profiles A-F

SRI profiles

Doctor James England
James England, MD, MSc, FRCPC

Associate Scientist

Sunnybrook Health Sciences Centre
2075 Bayview Ave., Room T2-047
Toronto, ON
M4N 3M5

Phone: 416-480-4662
Fax: 416-480-6002

Administrative Assistant: Ayesha Iqbal


  • Bachelor of Science, 2011, Honours Biochemistry, University of Waterloo, Canada
  • Doctor of Medicine, 2011, University of Toronto, Canada
  • Masters of Science, 2023 Clinical Epidemiology, Institute of Health Policy Management and Evaluation, University of Toronto, Canada

Appointments and Affiliations:

Research Foci:

  • Myeloproliferative neoplasms
  • Acute Leukaemia
  • Clinical Outcomes Research

Research Summary:

Dr. England has an interest in myeloid disease and published manuscripts on myelodysplastic syndromes, PNH, and acute myeloid leukemia. Dr. England has led projects evaluating the clinical and molecular features of JAK-inhibitor failure in myelofibrosis and outcomes with second-line therapies, and has coordinated the establishment and analysis of a pan-Canadian cohort of adolescent and adult patients with MPNs. Dr. England has an interest in expanding clinical trials available for acute and chronic myeloid malignancies.

Selected Publications:

See current publications list at PubMed.

  1. England JT, Szuber N, Sirhan S, Dunne T, Cerquozzi S, Hill M, Villeneuve PJ, Ho JM, Sadikovic B, Bhai P, Krishnan N. Clinical Features and Long-Term Outcomes of a Pan-Canadian Cohort of Adolescents and Young Adults with Myeloproliferative Neoplasms: A Canadian MPN Group Study. Leukemia. 2024 Feb 6:1-9.

  2. England JT, Atenafu EG, Kennedy JA, Goraya B, Cheung V, Nye T, Gauthier K, Davidson MB, Bankar A, Sibai H, Maze D. Comparison of clinical outcomes between transplant and nontransplant therapies in myelofibrosis following failure of first-line JAK-inhibitor. American journal of hematology. 2023 May;98(5):E127-9.

  3. England JT, Gupta V. Fedratinib: a pharmacotherapeutic option for JAK-inhibitor naïve and exposed patients with myelofibrosis. Expert Opinion on Pharmacotherapy. 2022 Oct 13;23(15):1677-86.

  4. England JT, McNamara CJ, Kennedy JA, Capo-Chichi JM, Huang J, Arruda A, Nye T, Cheung V, Claudio JO, Maze D, Sibai H. Clinical and molecular correlates of JAK-inhibitor therapy failure in myelofibrosis: long-term data from a molecularly annotated cohort. Leukemia. 2022 Jun;36(6):1689-92.